Trials that use: Intention-to-treat analysis
New to this method? Read the tutorial →
228 results
- GOYAIndependent statistical analysis of the GOYA phase 3 trial of obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in participants with CD20-positive diffuse large B-cell lymphoma, including trial design, progression-free survival, statistical methodology,…
- GRIPHONIndependent statistical analysis of the GRIPHON phase 3 trial of selexipag in pulmonary arterial hypertension, covering its randomized time-to-event endpoint, secondary analyses, statistical methods, confidence intervals, and interpretation.
- GS-US-236-0102Independent statistical analysis of GS-US-236-0102, a randomized phase 3 trial comparing Stribild with Atripla in antiretroviral treatment-naive adults with HIV-1 infection, including the Week 48 virologic-success endpoint, non-inferiority framework, Wald/z-test methodology, and…
- GS-US-236-0103Independent statistical analysis of GS-US-236-0103 (NCT01106586), a randomized phase 3 study comparing Stribild with ritonavir-boosted atazanavir plus Truvada in antiretroviral treatment-naive adults with HIV-1.
- GS-US-292-0104Independent statistical analysis of GS-US-292-0104 (NCT01780506), a randomized phase 3 trial comparing E/C/F/TAF with E/C/F/TDF in antiretroviral treatment-naive adults with HIV-1 infection, including its non-inferiority analysis, risk difference, confidence interval, and Cochran-Mantel-Haenszel…
- GS-US-292-0109Independent statistical analysis of GS-US-292-0109 (NCT01815736), a randomized phase 3 trial evaluating switching from a TDF-containing regimen to E/C/F/TAF in virologically suppressed HIV-1-positive participants.
- HER2CLIMB-02Independent statistical analysis of HER2CLIMB-02, the randomized phase 3 trial of tucatinib with ado-trastuzumab emtansine in advanced or metastatic HER2-positive breast cancer, including time-to-event methodology, reported efficacy estimates, safety, and statistical interpretation.
- Hokusai-VTEA complete statistical analysis of Hokusai-VTE, the randomized phase 3 trial comparing heparin/edoxaban with heparin/warfarin for symptomatic venous thromboembolism, including non-inferiority analysis, Cox modeling, bleeding outcomes, and statistical interpretation.
- HVTN 505Complete statistical analysis of HVTN 505, a randomized phase 2 trial of HIV-1 DNA plasmid and recombinant adenoviral vector vaccines in HIV-uninfected participants, including trial design, endpoints, Cox survival analyses, safety, and…
- IBCSG 23-01Independent statistical analysis of IBCSG 23-01, a randomized trial of axillary lymph node dissection versus no axillary lymph node dissection in women with node-negative breast cancer and sentinel lymph node micrometastases.
- ICARIA-MMIndependent statistical analysis of the phase 3 ICARIA-MM trial comparing isatuximab, pomalidomide, and dexamethasone with pomalidomide and dexamethasone in refractory or relapsed and refractory multiple myeloma.
- IMblaze370Independent statistical analysis of IMblaze370, a randomized phase 3 trial comparing cobimetinib plus atezolizumab and atezolizumab monotherapy with regorafenib in metastatic colorectal adenocarcinoma.
- IMbrave050Independent statistical analysis of IMbrave050, a randomized phase 3 trial of atezolizumab plus bevacizumab versus active surveillance as adjuvant therapy in hepatocellular carcinoma at high risk of recurrence after surgical resection or…
- IMpassion130Complete statistical analysis of IMpassion130, a randomized phase 3 trial of atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated metastatic triple-negative breast cancer.
- IMpassion131Independent statistical analysis of IMpassion131, a randomized phase 3 trial of atezolizumab plus paclitaxel versus placebo plus paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer.
- IMpower010Independent statistical analysis of IMpower010, the randomized phase 3 trial of atezolizumab versus best supportive care following chemotherapy in non-small cell lung cancer, including disease-free survival, time-to-event methodology, confidence intervals, and interpretation.
- IMpower132Independent statistical analysis of IMpower132, a phase 3 randomized trial of atezolizumab plus platinum-pemetrexed versus platinum-pemetrexed in chemotherapy-naive participants with stage IV non-squamous non-small cell lung cancer.
- IMpower133Independent statistical analysis of IMpower133 (NCT02763579), a randomized phase 3 trial of atezolizumab plus carboplatin and etoposide versus placebo plus carboplatin and etoposide in untreated extensive-stage small cell lung cancer.
- IMvigor010Independent statistical analysis of IMvigor010, the randomized phase 3 study of atezolizumab versus observation as adjuvant therapy after surgical resection for high-risk muscle-invasive urothelial carcinoma.
- IMvigor130Independent statistical analysis of IMvigor130, a randomized phase 3 trial of atezolizumab with platinum-based chemotherapy or as monotherapy in untreated locally advanced or metastatic urothelial carcinoma.
- IMvigor211Independent statistical analysis of the phase 3 IMvigor211 trial of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer, including overall survival, hazard ratios, confidence intervals, and…
- ISABELA 1Independent statistical analysis of ISABELA 1 (NCT03711162), a randomized phase 3 study of GLPG1690 in idiopathic pulmonary fibrosis, including FVC decline, disease progression, hospitalization, mixed-effects models, logistic regression, Cox models, and safety.
- ISABELA 2Complete statistical analysis of the ISABELA 2 phase 3 trial of GLPG1690 in idiopathic pulmonary fibrosis, including trial design, FVC decline, disease progression, hospitalization, survival endpoints, safety, statistical methodology, and interpretation.
- JAVELIN Bladder 100A detailed statistical analysis of the randomized phase 3 JAVELIN Bladder 100 trial of avelumab plus best supportive care versus best supportive care in patients with urothelial cancer, including trial design, time-to-event…
- JAVELIN Ovarian 100Independent statistical analysis of JAVELIN Ovarian 100, the phase 3 trial of avelumab-based strategies in previously untreated epithelial ovarian cancer, including progression-free survival, overall survival, statistical methodology, safety, and interpretation.
- KATHERINEIndependent statistical analysis of KATHERINE, the randomized phase 3 trial of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer and residual tumor following preoperative therapy.
- KEYNOTE-006Independent statistical analysis of KEYNOTE-006, a randomized phase 3 trial comparing two pembrolizumab dosing schedules with ipilimumab in participants with advanced melanoma.
- KEYNOTE-024Independent statistical analysis of KEYNOTE-024 (NCT02142738), including randomized trial design, progression-free survival, overall survival, objective response rate, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-062Independent statistical analysis of KEYNOTE-062, a randomized phase 3 trial of pembrolizumab monotherapy and pembrolizumab plus standard chemotherapy in advanced gastric adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- KEYNOTE-361Independent statistical analysis of KEYNOTE-361, the randomized phase 3 trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy alone in urothelial carcinoma, including primary and secondary endpoint analyses, statistical methods,…
- KEYNOTE-775Independent statistical analysis of KEYNOTE-775, evaluating lenvatinib plus pembrolizumab versus treatment of physician's choice in advanced endometrial cancer, with detailed interpretation of PFS, OS, response, quality-of-life, and statistical methods.
- KRYSTAL-12Independent statistical analysis of KRYSTAL-12, the phase 3 randomized trial of adagrasib versus docetaxel in patients with advanced non-small cell lung cancer with a KRAS G12C mutation.
- MARIPOSAAn independent statistical analysis of the MARIPOSA phase 3 trial of amivantamab plus lazertinib versus osimertinib in locally advanced or metastatic non-small cell lung cancer, including trial design, progression-free survival methodology, results,…
- METEORIndependent statistical analysis of the METEOR phase 3 trial of cabozantinib versus everolimus in metastatic renal cell carcinoma, including progression-free survival, overall survival, objective response rate, trial design, and statistical methodology.
- MIRASOLIndependent statistical analysis of the MIRASOL phase 3 trial of mirvetuximab soravtansine versus investigator's choice chemotherapy in platinum-resistant advanced ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.
- ML18147Independent statistical analysis of ML18147, a randomized phase 3 trial of bevacizumab plus chemotherapy in metastatic colorectal cancer, including overall survival, progression-free survival, response rate, statistical methodology, safety, and interpretation.
- MONALEESA-2Complete statistical analysis of MONALEESA-2, the randomized phase 3 trial of ribociclib plus letrozole versus placebo plus letrozole in postmenopausal women with advanced or metastatic breast cancer.
- MONALEESA-3Independent statistical analysis of MONALEESA-3 (NCT02422615), a randomized phase 3 trial of ribociclib plus fulvestrant versus placebo plus fulvestrant in advanced breast cancer.
- MONALEESA-7Independent statistical analysis of MONALEESA-7, a randomized phase 3 trial of ribociclib plus endocrine therapy and goserelin versus placebo plus endocrine therapy and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced…
- MOVe-AHEADIndependent statistical analysis of the phase 3 MOVe-AHEAD trial of molnupiravir for prevention of Coronavirus Disease (COVID-19) in adults, including endpoint definitions, score-based confidence intervals, reported results, safety, and statistical interpretation.
- NALAIndependent statistical analysis of NALA, a randomized phase 3 trial of neratinib plus capecitabine versus lapatinib plus capecitabine in HER2+ metastatic breast cancer after two or more prior HER2-directed regimens.
- NAVIGATE ESUSIndependent statistical analysis of NAVIGATE ESUS, a randomized phase 3 trial comparing rivaroxaban with aspirin in patients with recent embolic stroke of undetermined source, including time-to-event methods, primary and secondary results, safety,…
- NeoALTTOIndependent statistical analysis of the phase 3 NeoALTTO trial of lapatinib and trastuzumab in neoplasms of the breast, including pathological complete response, event-free survival, overall survival, landmark analyses, methodology, and interpretation.
- NIAGARAIndependent statistical analysis of the phase 3 NIAGARA trial of durvalumab plus gemcitabine/cisplatin in muscle invasive bladder cancer, covering pathologic complete response, event-free survival, secondary endpoints, methodology, and interpretation.
- NO16968Independent statistical analysis of NO16968 (NCT00069121), a randomized phase 3 trial of capecitabine plus oxaliplatin versus 5-FU/LV in colorectal cancer, including disease-free survival, relapse-free survival, overall survival, statistical methodology, and interpretation.
- OCEANSIndependent statistical analysis of the OCEANS phase 3 trial of carboplatin and gemcitabine plus bevacizumab versus placebo in patients with ovary, peritoneal, or fallopian tube carcinoma, including PFS, objective response, overall survival,…
- ODINIndependent statistical analysis of the ODIN phase 3 trial comparing once-daily versus twice-daily darunavir/ritonavir in early treatment-experienced HIV-1 infected patients, including non-inferiority methodology, logistic regression, ANCOVA, Cox models, confidence intervals, and reported…
- ODYSSEY OUTCOMESComplete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, safety, and statistical interpretation.
- OlympiAComplete statistical analysis of the OlympiA phase 3 trial of adjuvant olaparib versus placebo in patients with germline BRCA-mutated high-risk HER2-negative primary breast cancer, including trial design, time-to-event endpoints, statistical methods, reported…
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.